Ligand Pharmaceuticals Incorporated (LGND) Stock Price & How to Invest

Ligand Pharmaceuticals earns money three ways, and only one of them looks like a normal drug company. Royalties on partnered medicines were ~$48.0M of the ~$63.7M reported in the June 2026 quarter, split between rights carried as intangible royalty assets (Filspari at ~$13.6M, Kyprolis ~$7.0M, Ohtuvayre ~$4.1M, Rylaze ~$3.2M, plus Capvaxive, Vaxneuvance and teriparatide) and financial royalty assets accounted for more like loans (Qarziba ~$6.2M, an Ohtuvayre inventors stream ~$3.3M). Captisol, a modified cyclodextrin that makes poorly soluble injectable drugs formulable and sits inside products such as Amgen's Kyprolis and Baxter's Nexterone, added ~$8.0M of material sales. Contract revenue and milestone income supplied the remaining ~$7.7M. Ligand runs no salesforce and no manufacturing plant for the drugs it collects on, which is the whole point of the structure.

That structure explains the multiple. A ~$5.9B market value on ~$291M of trailing revenue is about ~20x sales, a number that would be indefensible for a product company and is merely expensive for a royalty book where revenue arrives with almost no cost of goods attached. Trailing GAAP net income of ~$197M puts the trailing P/E near ~32x, and full-year 2026 guidance calls for revenue of ~$270M to ~$310M, royalties of ~$225M to ~$250M, and adjusted earnings of ~$9.00 to ~$9.50 per share. On July 14, 2026 Ligand closed a ~$739M all-cash acquisition of XOMA Royalty (each share took ~$39.00 plus a contingent value right tied to litigation proceeds), more than doubling the portfolio and adding commercial names including Vabysmo, Ojemda and Miplyffa. The debate is straightforward: royalty streams are contractual and finite, so the case rests on management replacing the declining ones faster than they run off.

Ligand controls none of the products it earns from, so a partner's pricing decision, launch stumble or patent loss lands straight in royalty revenue with no operational lever to pull. Concentration is real and getting more so: Filspari alone was roughly ~28% of June-quarter royalties, while Kyprolis, Vaxneuvance and teriparatide all shrank year over year and Captisol material sales fell to ~$16.6M in the first half from ~$21.7M a year earlier. Reported earnings are noisy because mark-to-market swings on equity holdings flow through the income statement, which is how the March 2026 quarter produced a net loss despite positive operating income. About ~$1.16B of convertible notes now sits against a book of contractual but finite cash flows, and conversion pushes the share count above the ~21.8M diluted figure already used in the latest quarter. Ligand is separately in litigation with Viking Therapeutics over its termination of the TR-Beta license, and three complaints filed by tribal plaintiffs in 2019 name it within the opioid MDL in the Northern District of Ohio, where the company states no individualized allegations have been advanced against it.

11 analysts publish price targets on LGND, averaging $342.82 against a $294.60 price as of August 2026, or +16.4%. The published targets run from $247.00 to $390.00, a moderate spread, and the ratings split 10 buy, 0 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LGND forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Ligand Pharmaceuticals Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The royalty line is compounding, not just holding. June-quarter royalties rose ~32% year over year to ~$48.0M, and the growth came from launches rather than price. The most optimistic published target, $390.00, assumes this works close to its best case.

The case against. Ligand controls none of the products it earns from, so a partner's pricing decision, launch stumble or patent loss lands straight in royalty revenue with no operational lever to pull. The most pessimistic target, $247.00, is roughly what LGND is worth if this bites instead.

Read the full bull and bear case on LGND, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ligand Pharmaceuticals Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$291M, up ~55%
• Royalty revenue (Q2 2026): ~$48.0M, up ~32% year over year
• Net income (TTM): ~$197M, about ~$9.19 per share
• FY2026 guidance: revenue ~$270M to ~$310M, adjusted EPS ~$9.00 to ~$9.50
• Market cap and multiples: ~$5.9B, about ~20x trailing sales and ~32x trailing earnings
• Balance sheet (June 30, 2026): ~$1.36B cash and short-term investments, ~$1.16B convertible notes, before ~$739M paid for XOMA in July

A sales multiple is close to meaningless for a royalty book, because royalty revenue carries essentially no cost of goods and the expense base is an office of dealmakers rather than a commercial organisation. Measured against guided 2026 adjusted earnings of ~$9.00 to ~$9.50, the stock sits near ~31x, and management points to operating cash flow above ~$200M this year and around ~$300M next. What that price embeds is an assumption that fresh royalty purchases keep arriving at accretive terms.

Other names that sit close to LGND: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get LGND exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LGND sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LGND fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

LGND trades as a compounding royalty book rather than a pharma company, and the outcome turns on whether newly purchased streams keep outrunning the older ones that are already fading.

Whether LGND is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LGND a buy or a sell?, and where the stock could go from here in the LGND stock forecast.

For income investors, whether LGND pays a dividend and how the payout looks is covered in does LGND pay a dividend? And to weigh LGND against a peer, read the full side-by-side comparisons: LGND vs DRI and LGND vs BX.